Tel: 0113 4264300 |




Chris Meredith, Chairman, Arterius Limited, Chris is currently Group Chief Executive Officer of Advanced Medical Solutions Group plc (AMS), a role he has held since 2011. He joined AMS as Group Commercial Director in July 2005 following a successful 18-year career in international healthcare sales, marketing, and business development. His experience prior to joining AMS covered business-to-business contract manufacturing, product development and clinical research, as well as branded product sales all within the medical device, pharmaceutical or consumer healthcare markets.

Steve Parker, Chief Executive Officer, Arterius Limited, Steve has held a series of senior roles in International Medical Device companies over a period of 40 years. Starting his career with roles in engineering, marketing and sales with Marquette Electronics (later to become part of GE Medical Systems) and various national management roles at St Jude Medical inc.. Steve also served as European Director of Sales and Marketing for Vasomedical inc. and Managing Director of i-STAT Ltd. responsible for all European operations He was Senior Director, International Commercial Operations, at Abbott Laboratories with divisional commercial responsibility for all markets outside of North America. Most recently Steve served as Chief Executive Officer of Midlands based Creavo Medical Technologies.

Kadem Al-Lamee, Chief Technical Officer, Arterius Limited, co-founder of Arterius in 2009 and was co-founder of PolyBioMed Limited in 1996, serving as Technical Director before becoming Managing Director in 2001, when PolyBioMed was acquired by Lombard Medical Technologies. PolyBioMed was then purchased by Bayer Materials Science in 2009. He was integral to the development of the business throughout its history, including strategic development, fund-raising, technical development, and the establishment of its intellectual property portfolio. Previously he was Principal Scientist in polymer chemistry for Innovative Technologies plc(Currently Advance Medical Solution plc), managing research and development programmes in areas including wound dressings and coated urinary catheters. He has extensive research and teaching experience with an MSc and PhD in Polymer Chemistry from the University of Liverpool. He has over 40 years-experience in Biomaterials and Medical Devices, has published over 60 papers in international journals and holds 25 granted patents/patent applications. His main interests are biomaterials, surface modifications and the coating of materials commonly used in medical devices, drug delivery systems, hydrogels for medical applications, cardiovascular devices, wound-care products, urology, and tissue engineering devices. He has been successfully awarded many grants from the UK’s DTI, the Innovate UK, Yorkshire Forward, and European Commission for the research and development of healthcare projects.

Peter Mason, Non-Executive Director, Arterius Limited, joined the Board of Directors of Arterius in 2014. Mr Mason is a Managing Director in Barclays’ Investment Banking Division. With over 16 years experience in Investment Banking, his current role, based in London, is as Head of EMEA Financial Institutions Debt Capital Markets. He holds a BSc and MEng in Engineering, Economics & Management from Oxford University, UK, and a MBA from INSEAD, France. Mr Mason is also a member of the UK’s Association of Corporate Treasurers.

Ludvik Uhan, Non-Executive Director, Arterius Limited, joined the Board of Directors of Arterius in 2017 to represent Novoline d.o.o investment. Mr Uhan has MSc from the University in Ljubljana, Faculty of Economics in an International Economy, and his Thesis was entitled “Financial Measurement of marketing activities on B2B markets of Investment goods”. He has a long experience in new businesses formation of corporations, business structures, approving privacy policies and developing commercial transactions.

Paul Hedgeland, Non-Executive Director, Arterius Limited. Joined the Board in January 2021 to represent Deepbridge Capital Ltd. Mr Hedgeland is Director of PH Clinical Ltd, is NED to six UK SMEs and Advisor to a leading Site Management Organisation.
He has over 34 years experience in The Pharmaceutical Industry with GSK , and 14 years with The NIHR Clinical Research Networks, creating Greater Manchester CRN/World Wide Partnerships for research projects with the top Pharmaceutical Companies in many disease areas.

Barry Clare, Non-Executive Director, Arterius Limited. Barry joined the Board of Arterius in 2019. He is presently Deputy Chairman of the University of Manchester NHS Foundation Trust and is a pioneering business leader with extensive experience in the healthcare industry sector. He has held a number of top roles at leading international companies and has a proven track record in developing and implementing strategy in healthcare, retail, consumer products and financial services. Barry created Boots Healthcare International, the international “over the counter” consumer healthcare business of Boots Company plc., and through Barry’s leadership, the business became the fastest growing “over the counter” business in Europe. Following his career at Boots, Barry has been chairman of a number of successful, pioneering healthcare companies that have brought several ground-breaking innovative to the NHS. Barry’s portfolio of innovative healthcare solutions include, e-health business, diagnostic tests and medicine development.

Charlie Patel, Non-Executive Director, Arterius Limited, Charlie joined the Board of Arterius in 2020. He has BA Hons. In Economics and Law from the University of Leicester, UK. Charlie is presently Co-founder and Partner of Decisive Group, based in UAE. The group is always on a search for the most perspective investments, venture capital businesses, private equities, mergers, acquisitions and much more. The group consists of: Decisive Zone, Decisive Trading, Decisive Brokers, Decisive Consultants, Decisive Homes and Decisive Stay.


Dr Rasha Al-Lamee is an Interventional Cardiologist at Imperial College Healthcare NHS Trust. She studied at the University of Oxford and University College London. She went onto complete her training as a junior doctor on the Barts and the London Medical rotation before being appointed as a Specialist Registrar on the North West London Cardiology rotation in 2006. She has 9 years of Cardiology experience and completed three years of Interventional Fellowship training at Hammersmith Hospital in London. She also spent one year training as an Interventional Fellow under the supervision of Professor Antonio Colombo in Milan. She completed specialist training in 2013 and is currently working as an Interventional Cardiologist at Imperial College NHS Healthcare Trust and a Clinical Researcher at Imperial College London.

Her sub-speciality interests are complex coronary intervention, coronary physiology and invasive intravascular assessment. She is currently leading the ORBITA trial as part of a PhD programme under the supervision of Dr Justin Davies and Professor Darrel Francis. At Imperial College she is actively involved in the development and recruitment of a number of multi-centre clinical trials. She had over 20 peer-reviewed publications and has presented at international Cardiology conferences worldwide throughout her clinical career.


The Company funding is based on personal investments from the two founders and directors of the business, as well as from a co-investor director of Novoline d.o.o. in Ljubljana, Slovenia. The company has recently received an investment from Deepbridge Capital LLP.
Further investments to enable the Company to undergo full human clinical trials for regulatory purposes are envisaged, and therefore approaches from angel investors, VC funds and potential strategic partners would be welcome.


Neil Bressloff BA Hons (Oxon), PhD is Professor of Biomedical Engineering & Design and is Head of the Computational Engineering & Design Research Group in the Boldrewood Innovation Campus at the University of Southampton. As head of group, he is responsible for approximately 80 staff, post-doctoral researchers and PhD students. He sits on the Steering Committee for the Institute for Life Sciences, leads the Grand Challenge in Life Technologies and leads the Bioengineering and Human Factors Faculty Theme. He has over 20 years’ experience in computational engineering and design with allied expertise in computational fluid dynamics, finite element analysis and high performance computing, particularly applied in the field of cardiovascular engineering. He has published over 75 learned articles and won over £1.5m in grants in recent years, largely engaged with industry.

Professor Phil Coates, FR Eng (Professor of Polymer Engineering, Bradford University) is Director of the Polymer Centre of Industrial Collaboration, the Advanced Materials Engineering RKT Centre, and the International Centre for Polymer Microprocessing (a joint laboratory with Sichuan University). The research targets high value polymer products for a range of sectors – healthcare technology (including bioresorbable polymers for orthopaedic applications), pharmaceuticals processing, optical, automotive and advanced materials developments, including nanocomposites and reactive grafting, all with pioneering in-process measurement and modelling. He has published extensively – over 300 papers, in scientific journals and has co-authored 9 books, and edited 7 books. He holds 12 patents. He is Chief Editor of the IoM3 international journal, Plastics, Rubber and Composites: Macromolecular Engineering

Dr Adrian Kelly, BEng (Hons) PhD CEng (Reader in Polymer Engineering at the University of Bradford). His research interests include pharmaceutical polymer engineering, process monitoring, thermal optimisation, nanocomposites, biopolymers and recyclates. In 2010 he co-founded the Centre for Pharmaceutical Engineering Science with colleagues in Engineering and Life Sciences; he is also active in the Centre of Advanced Materials Engineering and the Centre for Polymer Micro and Nano Technology.

Professor Morgan Alexander (Professor of Biomedical Surfaces, Nottingham University) is the Director of the EPSRC Programme Grant in Next Generation Biomaterials Discovery, a Royal Society-Wolfson Research Merit Award holder and a Wellcome Trust Senior Investigator. His work involves developing materials for application in human healthcare and characterising relationships between surface structure and biological properties. Understanding these relationships is critical to the development of next generation biomaterials and it is the theme running through his group’s work across a variety of areas spanning controlling bacterial adhesion to stem cell response for application in medical devices and cell manufacture.
Dr Nicolas Foin is Scientific Lead for Medtech research at the National Heart Research Institute Singapore and Adjunct Associate Professor at Duke-National University of Singapore Graduate Medical School. His research expertise focuses on treatment of coronary heart diseases using minimally invasive approach, as well as pre-clinical diseases models and intravascular imaging. Regular speaker in international cardiac interventional congresses, he has to date published over 60 publications and book chapters in the field of cardiovascular interventions and intravascular OCT imaging. He has also collaborated with several large medical device companies and start-ups on new product developments.